Review reveals divergent overall survival outcomes among CDK4/6 inhibitors in HR-positive HER2-negative metastatic breast cancer, indicating shifting first-line selection preferences.
The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the first-line setting for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Randomized trials have demonstrated similar and significant improvements in progression-free survival using the three available CDK4/6 inhibitors and led to regulatory approval. However, mature overall survival data now suggest potential differences among the various agents, suggesting an evolution in selection preferences.
No takes yet. Share an insight, caveat, or question.
Grinshpun et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: